Market Place
Sourcing Support
Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD
09 Apr 2024 //
GLOBENEWSWIRE
Artios to Present Initial Phase 1 Monotherapy Data for ATR Inhibitor ART0380
05 Oct 2023 //
GLOBENEWSWIRE
Artios Announces Initiation of PII Trial for ATR Inhibitor ART0380 & Gemcitabine
09 Feb 2023 //
GLOBENEWSWIRE
Artios initiates Phase 2 study of Pol? Inhibitor ART4215
10 Aug 2022 //
GLOBENEWSWIRE
Artios Appoints Samantha Truex to Board of Directors
23 Jun 2022 //
GLOBENEWSWIRE
Artios` ART0380, Development On Track and Progressing Into Phase 1b Evaluation
05 Apr 2022 //
GLOBENEWSWIRE
Artios raises $153M to fund DNA damage repair clinical trials
27 Jul 2021 //
FIERCEBIOTECH
Artios raises $153M to fund DNA damage repair clinical trials
27 Jul 2021 //
FIERCEBIOTECH
Artios Pharma Publishes Preclinical Data on Small Molecule
17 Jun 2021 //
GLOBENEWSWIRE
Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration
08 Apr 2021 //
GENENGNEWS
Novartis taps Artios for targets to enhance radioligand drugs
07 Apr 2021 //
FIERCEBIOTECH
Artios Pharma Announces Collaboration with Novartis to Create Next
07 Apr 2021 //
ARTIOSPHARMA
Novartis taps DNA damage specialist Artios in $1.3B discovery deal
07 Apr 2021 //
ENDPTS
Artios, Novartis form cancer therapies collaboration
06 Apr 2021 //
PHARMATIMES
Artios Announces the Start of First Clinical Study with the Dosing of its ATR
11 Feb 2021 //
PRNEWSWIRE
Artios Announces the Start of First Study with the Dosing of its ATR, ART0380
10 Feb 2021 //
PRNEWSWIRE
Artios Pharma Expands US Leadership Team with the Appointment
12 Jan 2021 //
PRNEWSWIRE
Merck KGaA agrees research deal with Artios for `DNA damage` cancer drugs
04 Dec 2020 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.